Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery

K. Onizawa, K. Uchiyama, H. Iwabuchi, K. Tsunoda, Y. Okada, S. Asanami

研究成果: Article査読

抄録

Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery. ABK was administered by intravenous drip infusion at a close of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously. The clinical efficacy rate of ABK was 77.8%. As to the bacteriological effect. MRSA was eradicated in 4 (44.4%) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0% in 5 monotherapy cases and 83.3% in 4 combined therapy cases. In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.

本文言語English
ページ(範囲)10-14
ページ数5
ジャーナルOral Therapeutics and Pharmacology
16
1
出版ステータスPublished - 1997 1 1

ASJC Scopus subject areas

  • Dentistry(all)
  • Pharmacology
  • Pharmacology (medical)

フィンガープリント 「Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル